Cellular Dynamics

Large scale in vitro screening for potential therapeutics and off-target effects is required to provide safe and effective treatments. Excised rodent tissue and transformed cells have been used for neuronal drug discovery and safety pharmacology screens; however, a model system based on human physiology must be incorporated in order to provide clinically relevant data.

CDI has addressed this need by providing researchers with iCell GlutaNeurons; commercial quantities of human iPSC-derived glutamatergic neurons that form connected networks which burst synchronously. By observing the modulation of network activity during a compound screen, researchers can quickly identify potential therapeutics and detect compounds with adverse effects early in the drug discovery process.

To learn how iCell GlutaNeurons can be used to assess compound modulation of human neuronal activity, please enjoy the following video!

Using iCell GlutaNeurons for Safety Pharmacology and Drug Discovery

Learn how advances in human induced pluripotent stem cell (iPSC) technology enable early detection and avoidance of neuro-, cardio-, and hepatotoxicity during drug development. The Cellular Dynamics line of iCell® products are fully differentiated human cells derived from iPSCs. iCell GlutaNeurons are a population of excitatory neurons that bring previously inaccessible human biology to the lab bench for both discovery and toxicity (seizurogenic) investigations. iCell Hepatocytes 2.0 maintain appropriate function longer than existing models and over extended culture periods, thus providing a relevant means for acute and sub-chronic toxicity testing in human tissue cells. iCell Cardiomyocytes2 exhibit electrical and contractile behavior that is translatable to both the human condition and more costly animal models. This webinar will provide examples from industry experts on how iPSC technology can have a meaningful impact on your day to day research.

Speakers:
Brad Swanson, PhD, Vice President, R&D: Cell Biology, Cellular Dynamics International

Andrew Bruening-Wright, PhD, Principal Scientist, Charles River Laboratories

William Proctor, PhD, DABT, Scientist, Investigative Toxicology, Department of Safety Assessment, Genentech

Refining Toxicity Testing through Advances in Human iPSC Technology

Given the challenges of replicating Parkinson’s disease in animal models, returning to models that are human-based and highly clinically characterized may provide the most successful path forward. There is a critical need to differentiate Lewy body Parkinson’s disease from other non-Lewy body forms of parkinsonism. This is important because the underlying molecular pathomechanisms, and hence potential therapeutic targets, are unlikely to be similar for both.

The Promise and Challenges of iPSC Modeling in Parkinson’s Disease

Customer Stories: Salman Khetani, PhD, Colorado State University, discusses his use of iPSC-derived human hepatocytes for toxicology testing.

Patterned Co-culture of iCell Hepatocytes for Drug Toxicology and De-risking Drug Development

Jordan Lancaster, University of Arizona discussed his research in regenerative medicine applications of human  iPSC-derived cardiomyocytes to treat heart failure

Development of a Cell-based Therapeutic Heart Patch for the Treatment of Heart Failure 

Ross Whittaker, Vala Scieces, discusses imaging technologies for identifying arhythmogenic compounds with the Kinetic Image Cytometer

Cellular Dynamics

Home

Videos

Playlists

About

Keep up to date with all your favourite videos and channels.

Get personalised notifications on new releases and channel content by subscribing to the LabTube eNewsletter.